Last reviewed · How we verify
NCT05374915
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
Phase 2 trial testing REM-001 photodynamic therapy in Cutaneous Breast Cancer in 15 participants. Participants enrolled and being followed up; not accepting new ones.
30 December 2025
Quick facts
| Lead sponsor | Kintara Therapeutics, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 12 February 2024 |
| Primary completion | 30 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- REM-001 photodynamic therapy
Conditions studied
- Cutaneous Breast Cancer — all drugs for Cutaneous Breast Cancer →
Sponsor
Kintara Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Cutaneous Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single cohort study to confirm dose, assessments and timing of response, to support future studies. The primary objective of the trial is to evaluate cutaneous tumor response within total target treatment field to REM-001 therapy assessed using standardized digital photography
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent Progress in Photothermal, Photodynamic and Sonodynamic Cancer Therapy: Through the cGAS-STING Pathway to Efficacy-Enhancing Strategies.
Fang K, Zhang H, Kong Q, Ma Y, et al · · 2024 · cited 7× · PMID 39125107 · DOI 10.3390/molecules29153704 -
Umbrella review of photodynamic therapy for cancer: efficacy, safety, and clinical applications.
Chen H, Li H, Li HJ, Zhang Z. · · 2025 · cited 2× · PMID 40831922 · DOI 10.3389/fonc.2025.1528314 -
The Effect of Myc Inhibition Combined with the Synergistic Effect of Photothermal, Photodynamic and Radiotherapy in Tumor Treatment.
Cui Y, Yang W, Liu W, Li Y, et al · · 2025 · PMID 41103361 · DOI 10.2147/ijn.s526592
Verify or expand the search:
- PubMed search for NCT05374915
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Kintara Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT03050736 — Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression · Phase 2 · completed
- NCT02717962 — Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting · Phase 2 · completed
- NCT03138629 — Expanded Access to VAL-083 · no longer available
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05374915 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kintara Therapeutics, Inc.
- Last refreshed: 28 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05374915.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing